Denosumab as First‑Line and Refractory Therapy for Malignant Hypercalcemia

First‑Line Recommendation (Endocrine Society Guidelines)

• The Endocrine Society recommends denosumab 120 mg subcutaneously as the preferred first‑line agent over intravenous bisphosphonates for adults with hypercalcemia of malignancy; the evidence quality is low and the recommendation is conditional. 1

Dosing and Administration (Praxis Medical Insights)

• For patients with mild‑to‑moderate hypercalcemia (corrected calcium < 14 mg/dL or < 3.5 mmol/L), administer denosumab 120 mg subcutaneously as monotherapy. 3

Severity‑Based Treatment Algorithm

Severe Hypercalcemia (Corrected Calcium ≥ 14 mg/dL or ≥ 3.5 mmol/L) – Adjunctive Calcitonin (Endocrine Society)

• Add calcitonin 80–160 units per day to denosumab to achieve a more rapid reduction in serum calcium. 1
• Limit calcitonin use to a maximum of 48–72 hours because tachyphylaxis develops and longer exposure provides no additional benefit. 1

Rationale for Calcitonin (Praxis Medical Insights)

• Calcitonin offers a faster initial calcium decline while awaiting the peak effect of denosumab. 3

Refractory or Recurrent Hypercalcemia (Endocrine Society)

• In patients whose hypercalcemia persists or recurs despite intravenous bisphosphonate therapy, switch to denosumab 120 mg. This strategy is endorsed as a key indication for denosumab. 1